| 
Real-world outcomes of patients with advanced non-small cell lung cancer (aNSCLC) and autoimmune disease (AD) receiving immune checkpoint inhibitors (ICIs).  | 
|   | 
 | 
No Relationships to Disclose  | 
|   | 
 | 
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); HERON (Inst); Lilly (Inst); Lilly (Inst); Merck (Inst); Merck KGaA (Inst); Merck KGaA (Inst); Pfizer (Inst); Sanofi (Inst)  | 
|   | 
 | 
Employment - Celgene; Concerto HealthAI  | 
Stock and Other Ownership Interests  - Celgene  | 
|   | 
 | 
Employment - Concerto HealthAI  | 
Stock and Other Ownership Interests  - Concerto HealthAI  | 
|   | 
 | 
Consulting or Advisory Role - Bristol-Myers Squibb  | 
Research Funding - Amgen (Inst); AstraZeneca (Inst); Eisai (Inst); Genentech (Inst); Lilly (Inst); Merck (Inst); Pfizer (Inst)  | 
Travel, Accommodations, Expenses - Bristol-Myers Squibb  | 
|   | 
 | 
No Relationships to Disclose  | 
|   | 
George Anthony  Komatsoulis  | 
No Relationships to Disclose  | 
|   | 
 | 
Employment - Concerto HealthAI  | 
|   | 
 | 
No Relationships to Disclose  | 
|   | 
 | 
No Relationships to Disclose  | 
|   | 
 | 
 | 
 | 
Stock and Other Ownership Interests  - Tempus  | 
Patents, Royalties, Other Intellectual Property - Tempus  | 
|   | 
 | 
 | 
Stock and Other Ownership Interests  - Tempus  | 
Patents, Royalties, Other Intellectual Property - Tempus  | 
|   | 
 | 
No Relationships to Disclose  |